Post marketing study to evaluate the safety and performance of Everpro Everolimus-Eluting Coronary Stent System (EES) in all-comer patients with coronary artery disease (CAD) in routine clinical practice
- Conditions
- Health Condition 1: I259- Chronic ischemic heart disease, unspecified
- Registration Number
- CTRI/2020/07/026564
- Lead Sponsor
- Sahajanand Laser Technology Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1. Males and Females more than 18 years of age.
2. Subjects who had signed the Hospital consent form.
3. The subjects who have been treated with PCI and implanted with Everpro Drug Eluting Stent as a part of their treatment of Coronary Artery Disease, without any further indication for Emergent Coronary Artery Bypass Graft Surgery
1. Subjects who were not eligible for a PCI procedure. Or who were candidates for Urgent or planned elective Coronary Artery Bypass Surgery.
2. Subjects who are treated with stents other than Everpro stent.
3. Subjects who are known sensitive to Cobalt Chromium alloy, PLLA Polymer, Everolimus and its Analogues, Aspirin, Clopidogrel and analogues, and Contrast media.
4. Pregnant/lactating women during Index procedure. However, if pregnancy occurs during followâ??ups, the subject will not be excluded.
5. Subjects with more than Grade III Renal Insufficiency as indicated by Creatinine > 160 mcmol/L.
6. Subjects with short life expectancy less than the trial duration of 1 years (including patients with cancer, HIV/AIDS), documented LVEF <30%, history of Cardiac Failure, Structural heart disease, Myocardiopathies, Arrhythmia or other Comorbid conditions
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To determine the safety and performance of the Everpro Everolimus-Eluting Coronary Stent System (EES) in allcomer patients with coronary artery disease (CAD) in 6 month clinical follow-upTimepoint: 6 months
- Secondary Outcome Measures
Name Time Method 1) To evaluate the Efficacy of the Device by evaluating the Frequency of Clinically Driven Target lesion Revascularization. 2) To evaluate Clinical Safety of Device in terms of Deaths and Myocardial Infarction up to 1 years. 3) To evaluate Stent Thrombosis up to 1 years from day of stent implant.Timepoint: 1 year
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.